Synutra International

The Company is engaged in the production, distribution and sale of dairy-based nutritional products under the Shengyuan or Synutra line of brands. The Company operates through three segments: Nutritional Food, which includes the sale of powdered infant and adult formula products, with brands, including Super, My Angel and Dutch Cow, as well as the sale of prepared foods under the brand of Huiliduo; Nutritional Supplement, which includes the production and sale of nutritional supplements, such as chondroitin sulfate to third-parties and microencapsulated Docosahexanoic Acid and Arachidonic Acid to the nutritional food segment for use in powdered formula production, and Other Business, which includes non-core businesses, such as ancillary sales of excess or unusable ingredients and materials to industrial customers; provision of genetic diagnostic services for new born babies, and sales of cosmetics to pregnant women.
Rockville, US
Size (employees)
2,600 (est)
Synutra International is headquartered in Rockville, US

Synutra International Office Locations

Synutra International has an office in Rockville
Rockville, US (HQ)
500 2275 Research Blvd

Synutra International Data and Metrics

Synutra International Financial Metrics

Synutra International's revenue was reported to be $365 m in FY, 2016 which is a 12% decrease from the previous period.
Numbers are in $, USD

Revenue (FY, 2016)

365 m

Revenue growth (FY, 2015 - FY, 2016), %


Gross profit (FY, 2016)

176.8 m

Gross profit margin (FY, 2016), %


Net income (FY, 2016)

21 m

EBIT (FY, 2016)

46.5 m

Market capitalization (15-May-2017)

343 m

Closing share price (15-May-2017)


Cash (31-Mar-2016)

102.7 m


651.3 m
Synutra International's current market capitalization is $343 m.
FY, 2014FY, 2015FY, 2016


370.5 m413.9 m365 m

Revenue growth, %


Cost of goods sold

217 m224.4 m188.2 m

Gross profit

153.5 m189.6 m176.8 m

Gross profit Margin, %


General and administrative expense

25.5 m28 m27.7 m

Operating expense total

25.5 m28 m27.7 m


41.6 m73.7 m46.5 m

EBIT margin, %


Interest expense

16.2 m16 m16.4 m

Interest income

4.7 m7.6 m8.8 m

Income tax expense

130 k(4.4 m)5.5 m

Net Income

30.3 m72 m21 m
FY, 2014FY, 2015FY, 2016


90.9 m85.2 m102.7 m


84 m87.8 m98.4 m

Current Assets

285.3 m382.9 m362 m


145.8 m187.1 m294.2 m

Total Assets

550.7 m664.9 m817.1 m

Accounts Payable

39.6 m47.8 m76.9 m

Total Debt

252 m275.1 m411 m

Current Liabilities

310.3 m386.8 m345.2 m

Additional Paid-in Capital

135.4 m135.4 m134.7 m

Retained Earnings

(104.6 m)(35 m)(14.8 m)

Total Equity

61.3 m114.6 m136.8 m

Debt to Equity Ratio

4.1 x2.4 x3 x

Debt to Assets Ratio

0.5 x0.4 x0.5 x

Financial Leverage

9 x5.8 x6 x
FY, 2014FY, 2015FY, 2016

Net Income

30.3 m72 m21 m

Depreciation and Amortization

15.4 m15.2 m9.5 m

Accounts Receivable

16 m(380 k)(13.7 m)


(1.2 m)(18.2 m)(24.2 m)

Accounts Payable

(8.7 m)8.5 m27.8 m

Cash From Operating Activities

46.2 m62.5 m29.7 m

Purchases of PP&E

(29.6 m)(89.3 m)(103.8 m)

Cash From Investing Activities

(86.7 m)(123.3 m)(102 m)

Long-term Borrowings

(111.9 m)(139.4 m)(149 m)

Cash From Financing Activities

50.8 m57.2 m91.3 m

Interest Paid

17.3 m
Y, 2016


14 x


22 x


3 x


0.5 x

Financial Leverage

6 x

Synutra International Market Value History

Synutra International Company Life and Culture

You may also be interested in